Why the distinction matters
Exosome products are often discussed under section 351 biologic-drug frameworks. Catalog placement next to a tissue allograft does not complete classification.
Expect different documentation questions and marketing constraints for exosome SKUs versus Wharton's jelly allografts.
Procurement is not permission
Opening a verified account and receiving a shipment are procurement steps. They do not authorize a clinical application.
Keep procurement owners and counsel reviewers on separate tracks with written handoffs.
Claim discipline as a risk signal
Aggressive live-cell or disease claims are a procurement risk signal even when prices look attractive.
Favor clear not-a-stem-cell-therapy framing and counsel-friendly language in any co-marketing.
Operational checklist for section 351 vs 361 exosomes
Before ordering under the topic section 351 vs 361 exosomes, confirm storage class, receiving owner, and which documents will be required at release.
Close open items in writing. Do not infer missing COA fields from a different lot or SKU.
Frequently asked questions
Does Precision Biologics certify regulatory status for our use?+
No. Classification and intended-use determinations belong to the ordering physician and clinic counsel.
Is this legal advice?+
No. This is general information for licensed healthcare professionals.
Can account approval replace counsel review?+
No. Account verification is administrative only.
Does this page determine how we may use products discussed under section 351 vs 361 exosomes?+
No. Intended use remains with the ordering physician and clinic counsel.